title: Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease.
abstract: After infections, thromboembolism is considered by many experts to be the most significant life-threatening complication of nephrotic syndrome. The purpose of this review is to summarize the epidemiology, clinical and molecular pathophysiology, and management of this complication. Children (2.8%) are less likely than adults (26.7%) with nephrotic syndrome to develop thromboembolism. However, infants and children aged >12 years are at much greater risk. Membranous histologic changes increase thromboembolic risk at all ages; in particular, adults with membranous nephropathy have the highest reported risk (37.0%) and children with membranous histology have a rate (25%) that approaches the overall adult rate. There are striking, but variable, pathologic alterations of molecular hemostasis associated with nephrotic syndrome. No clear molecular therapeutic targets have been identified, but most studies show that the major pathologic changes involve antithrombin, fibrinogen, and factors V and VIII. There is inadequate evidence to support routine prophylactic therapy. Therapy includes anticoagulation in all cases, with thrombolysis reserved for those with the most severe thromboembolic disease. Future hemostatic research in nephrotic syndrome should focus on identifying cohorts at highest risk for thrombosis through the use of clinical markers and biomarkers as well as searching for molecular targets to correct the prothrombotic pathophysiology of this disease.
authors.affiliation: Department of Pediatrics, The Ohio State University College of Medicine, Columbus, USA. Bryce.Kerlin@NationwideChildrens.org
authors.forename: Bryce A
authors.initials: BA
authors.lastname: Kerlin
authors.forename: Rose
authors.initials: R
authors.lastname: Ayoob
authors.forename: William E
authors.initials: WE
authors.lastname: Smoyer
mesh_terms: D000328:Adult; D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D009404:Nephrotic Syndrome / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology*; D018570:Risk Assessment; D012307:Risk Factors; D013923:Thromboembolism / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology*; D015912:Thrombolytic Therapy; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents